Cancer screening study for HIV-infected patients by blood transfusio
Not Applicable
Recruiting
- Conditions
- HIV infectionHIV-1, cancerD046650
- Registration Number
- JPRN-jRCT1032220397
- Lead Sponsor
- Watanabe Koji
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1.HIV infected person caused by transfusions of HIV-tainted blood products
2.A written informed consent was obtained
Exclusion Criteria
1.Severe underlying and/or active AIDS disease that need to be treated
2.Patients who have difficulty to participate in this study due to psychological disease
3.Patients who are judged to be inappropriate in participation by the attending docter
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To demonstrate incidence(per 100 person-year) of the NADM among HIV infected patients by blood <br>transfusion
- Secondary Outcome Measures
Name Time Method Identification of the risk factors for NADM among HIV infected patients by blood transfusion
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link HIV infection to increased cancer risk in jRCT1032220397 trial participants?
How does blood transfusion-based cancer screening compare to standard imaging techniques for HIV-infected patients?
What biomarkers are being evaluated in JPRN-jRCT1032220397 to predict cancer development in HIV-1-infected individuals?
What adverse events are associated with blood transfusion-based cancer screening in immunocompromised HIV patients?
Are there alternative cancer screening approaches for HIV-infected patients with co-morbid conditions like D046650?